Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.
Tirzepatide keeps showing up as a research peptide to watch, and the latest data from the Hokkaido-TZP study backs that up—especially for researchers focused on older subjects with type 2 diabetes. This real-world analysis looked at 199 patients over 65 (average age: 71.3) using tirzepatide and tracked what actually happened in the clinic, not just in a controlled trial.
Endocr J
by Kitsunai H, Maruyama F, Miyano Y et al.
“Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters. Kitsunai H(1), Maruyama F(1), Miyano Y(2), Abe T(2), Kurihara H(3), Tsuji K(4), Abiko A(4), Miyamoto Y(5), Homma R(6), Nakamura A(7), Nomoto H(1); Hokkaido-TZP Study Group. Author information: (1)Division of Endocrinology, Metabolism, and Rheumatology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido 078-8510, Japan. (2)Sapporo Diabetes and Thyroid Clinic, Hokkaido 060-0807, Japan. (3)Kurihara Clinic, Hokkaido 004-0053, Japan. (4)Department of Diabetology and Endocrinology, Japanese Red Cross Asahikawa Hospital, Hokkaido 070-0061, Japan. (5)Department of Diabetology and Endocrinology, Asahikawa City Hospital, Hokkaido 070-8610, Japan. (6)Department of Metabolism and Endocrinology, Asahikawa-Kosei General Hospital, Hokkaido 078-8211, Japan. (7)Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido 060-8648, Japan. In an aging society, the establishment of safe and effective treatment strategies for older patients with type 2 diabetes is crucial. We performed a secondary analysis of the Hokkaido-TZP study (UMIN000056962), evaluating the real-world outcomes of tirzepatide in patients aged ≥65 years. Of 213 patients in the safety analysis set, 11 (5.2%) discontinued treatment because of adverse events, primarily gastrointestinal symptoms. In the effectiveness analysis set (n = 199; mean age 71.3 years, glycated hemoglobin [HbA1c] 7.79%), tirzepatide significantly reduced both HbA1c and body mass index over 6 months in the Young-old (65-74 years) and Old-old (≥75 years) groups. Notably, even among the 148 patients (74.4%) using agents associated with a risk of hypoglycemia (insulin, sulfonylureas, or glinides) at baseline, a substantial proportion (66.9%) achieved an HbA1c <7.0%. The physicians proactively adjusted these concomitant medications in 39.2% of users, but despite these preemptive reductions, this subgroup still achieved a reduction in HbA1c comparable to that of the entire cohort, and no severe hypoglycemia was reported. A significant reduction in body weight occurred, and this was more pronounced in glucagon-like peptide-1 receptor agonist-naïve patients and those taking fewer hypoglycemia-inducing agents. Furthermore, the tirzepatide dose tended to be lower in the patients who achieved greater weight loss. These findings suggest that although tirzepatide is highly effective, even in older adults, its safety must be optimized through preemptive reductions in the doses of concomitantly administered secretagogues and careful monitoring, to prevent excessive reductions in HbA1c and weight loss in this vulnerable population.”
Key takeaway: Tirzepatide drove down both HbA1c and body mass index (BMI) over six months. That held true for both the “young-old” (65-74) and the “old-old” (75+). Over two-thirds of those using baseline hypoglycemia-inducing agents (insulin, sulfonylureas, glinides) hit their HbA1c target under 7.0%. No severe hypoglycemia events turned up—even though most of these patients were already considered higher risk.
Researchers got proactive by lowering or adjusting other hypoglycemia-inducing meds in nearly 40% of cases. It worked. HbA1c reduction stayed on par with the rest of the group, and nobody bottomed out.
A few more points for the research crowd:
Weight loss was significant, especially in GLP-1 receptor agonist-naïve subjects and those on fewer secretagogues.
The greatest weight drops actually happened with lower tirzepatide doses.
Only 5% discontinued, mostly due to GI symptoms—no major surprises there.
The message: tirzepatide looks robust for glucose and weight endpoints in older populations, but it pays to manage background medications smartly. If you’re mapping out dosing or combination protocols, check out the research tools for planning.
This study makes a strong case for including tirzepatide in research targeting older adults—just keep an eye on those concurrent agents.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.